Bone

• One of the latest trends among celebrities is the “one meal a day” diet (or “Omad”).
• Omad is essentially a more extreme version of other types of fasting diets, such as intermittent fasting and time-restricted eating.

Fasting and health

• Or they are based on the assumption that if other forms of fasting can benefit health, then Omad will too.
• And it has other health benefits such as lowering blood pressure.
• One review study also found that many different types of fasting (including intermittent fasting and fasting every other day) can improve several aspects of metabolism.

Just one meal

• For half of the study, participants ate these calories in a single meal, before switching and eating their daily calories split into three meals per day.
• When participants ate just one meal per day, they saw a greater reduction in their body weight and fat mass.
• However, participants also had greater reductions in lean mass and bone density when eating just one meal a day.
• It will also be interesting to know whether the timing of the meal can further improve the results and if the nutritional profile of the meal makes a difference.

Other downsides

• Not getting enough of these important nutrients could lead to loss of muscle mass, risk of constipation and poor gut health.
• For most of us, this kind of diet could be unsustainable – and potentially harmful in the long run.

• Bioretec is the first and currently, the only medical device company to offer bioresorbable metal implants in the United States, the largest single market for orthopedic trauma products globally.
• RemeOs™ trauma screws are based on a proprietary bioactive and osteopromotive magnesium alloy introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes.
• Bioresorbable metals combine the surgical techniques of traditional metal implants and the patient-friendly care and benefits of last-generation bioresorbable polymer implants.
• Bioretec submitted the De Novo market authorization request to the FDA for the RemeOs™ trauma screw in May 2022.

• The RemeOs™ trauma screw is the first and currently only bioresorbable metal implant approved by the U.S. Food and Drug Administration (FDA).
• Bioresorbable metals combine the surgical techniques of traditional metal implants and the patient-friendly care and benefits of last-generation bioresorbable polymer implants making implant removal operations redundant.
• "This FDA market approval is the most important milestone in our company's history to date," comments Timo Lehtonen, CEO of Bioretec."
• For the first time, that market is now offered a bioresorbable alternative to be used instead of titanium and steel implants.

• The results of “Subcutaneous Testosterone Pellet Therapy for Reversal of Male Osteoporosis: A Review and Case Report” were published in the peer-reviewed medical journal “The Aging Male,” the official journal of the International Society for the Study of the Aging Male.
• After three months the patient’s testosterone level was up to 943 ng/dL, and after one year of continued testosterone therapy the patient’s repeated DEXA scan showed an improvement to his composite bone density, substantially normalizing his total hip bone density.
• The patient also returned to performing triathlons one year after the beginning of testosterone pellet therapy.
• Low testosterone in men is associated with a clear decrease in bone mineral density, which in turn is associated with a significant increase in bone fractures.